Figure S3


A
MEF
GFP-CHMP4B
TSZ
0 min
TSZ
65 min
B
RIPK3-2Fv-NIH3T3
WT
B/B 0 min
B/B 10 min
37/40
Mlkl-/-
GFP-CHMP4B
1/28
C
hMLKL(1-140)-
2Fv-Venus
-MEF Mlkl-/-
CHMP4B-
mCherry
-
+
CHMP4B-
mCherry
CHMP4B
Actin
D
200μg/mL
Digitonin treated
CTRL
B/B
hMLKL(1-140)-
2Fv-Venus
-MEF Mlkl-/-
243±5
237±10
336±5
314±15
hMLKL(1-140)-
2Fv-Venus
-MEF Mlkl-/-
+Dox
369±15
521±8
**
333±12
321±3
hMLKL(1-140)-
2Fv-Venus
-MEF Mlkl-/-
+hCHMP4B
-mCherry
239±11
240±8
513±66
493±17
hMLKL(1-140)-
2Fv-Venus
-MEF Mlkl-/-
+Dox
+hCHMP4B
-mCherry
389±13
567±10
**
476±11
716±14
**
MLKL1-140-2Fv-
Venus
hCHMP4B-
mCherry
E
RIPK3-2Fv-NIH3T3
WT
Mlkl-/-
1411±64
1609±48
*
473±7
482±12
200μg/mL
Digitonin
treated
CTRL
B/B
hCHMP4B-mCherry
F
hMLKL(1-140)-2Fv-Venus-MEF Mlkl-/-
+hCHMP4B-mCherry
B/B 0 min
B/B 15 min
siSCR
99/107
siTSG101
4/91
G
hMLKL (1-140)
-2Fv-Venus
hCHMP4B-
mCherry
DAPI
MERGE
siSCR
siTSG101